Literature DB >> 15905873

The prevalence of low vision and blindness in Canada.

D A L Maberley1, H Hollands, J Chuo, G Tam, J Konkal, M Roesch, A Veselinovic, M Witzigmann, K Bassett.   

Abstract

PURPOSE: The purpose of this study was to ascertain the prevalence and primary causes of visual impairment in a representative Canadian population.
METHODS: We reviewed a representative sample of patients who attended ophthalmologists' offices in a medium-sized Canadian city between 1996 and 2001 in order to estimate the prevalence of visual impairment. Demographic data, visual diagnoses, best-corrected visual acuities (BCVA), and visual field information were recorded. Visual status was categorized based on accepted World Health Organization (WHO) and North American criteria. Population data were obtained from the Canadian census.
RESULTS: The prevalence of low vision and blindness in our population was 35.6 and 3.8 per 10 000 individuals, according to the WHO classification, and 71.2 and 23.6 per 10 000 individuals, using the North American definition. Among individuals with some vision loss (vision worse than 20/40), cataract and visual pathway disease were the most common causes, together accounting for 40% of visual impairment. Age-related macular degeneration and other retinal diseases were the next most common causes of vision loss. Diabetic retinopathy and glaucoma were less frequently encountered as causes of visual impairment.
CONCLUSION: The overall prevalence of low vision and blindness in Canada are in keeping with data from large population-based studies from other developed nations. Cataract, visual pathway disease, and macular degeneration are the leading causes of visual impairment. These results are important for enhancing our understanding of the scope of vision health in Canada and may direct future health planning and cost-utilization research.

Entities:  

Mesh:

Year:  2006        PMID: 15905873     DOI: 10.1038/sj.eye.6701879

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  46 in total

1.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

2.  Quantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.

Authors:  Jae Hui Kim; Young Suk Chang; Dong Won Lee; Chul Gu Kim; Jong Woo Kim
Journal:  Jpn J Ophthalmol       Date:  2017-11-29       Impact factor: 2.447

3.  Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings.

Authors:  Brenda J Wilson; Susan Courage; Maria Bacchus; James A Dickinson; Scott Klarenbach; Alejandra Jaramillo Garcia; Nicki Sims-Jones; Brett D Thombs
Journal:  CMAJ       Date:  2018-05-14       Impact factor: 8.262

4.  The legibility of prescription medication labelling in Canada: Moving from pharmacy-centred to patient-centred labels.

Authors:  Susan J Leat; Kristina Ahrens; Abinaya Krishnamoorthy; Deborah Gold; Carlos H Rojas-Fernandez
Journal:  Can Pharm J (Ott)       Date:  2014-05

5.  Impact of examinees' stereopsis and near visual acuity on laparoscopic virtual reality performance.

Authors:  Henry Hoffmann; Rebecca Ruiz-Schirinzi; David Goldblum; Salome Dell-Kuster; Daniel Oertli; Dieter Hahnloser; Rachel Rosenthal
Journal:  Surg Today       Date:  2014-10-11       Impact factor: 2.549

6.  Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane.

Authors:  Katyanne Dantas Godeiro; Ana Carolina de Arantes Frota; Emilia Antecka; Alexandre Nakao Odashiro; Shawn Maloney; Bruno Fernandes; Miguel Noel Burnier
Journal:  J Carcinog       Date:  2006-08-15

7.  The Prevalence of Visual Impairment in the Adult Population.

Authors:  Christian Wolfram; Alexander K Schuster; Heike M Elflein; Stefan Nickels; Andreas Schulz; Philipp S Wild; Manfred E Beutel; Maria Blettner; Thomas Münzel; Karl J Lackner; Norbert Pfeiffer
Journal:  Dtsch Arztebl Int       Date:  2019-04-26       Impact factor: 5.594

8.  Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.

Authors:  Jae Hui Kim; Dong Won Lee; Young Suk Chang; Jong Woo Kim; Chul Gu Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-26       Impact factor: 3.117

9.  Phakic intraocular lenses for the treatment of refractive errors: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-10-01

10.  Prevalences and causes of vision impairment in elderly Chinese: a socioeconomic perspective of a comparative report nested in Jiangsu Eye Study.

Authors:  Rong-Rong Zhu; Jian Shi; Mei Yang; Huai-Jin Guan
Journal:  Int J Ophthalmol       Date:  2016-07-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.